AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (3.2 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Rapid Communication | Open Access

APE1 inhibition-promoted pyroptosis triggers T-cell infiltration and enhances anti-tumor immunity in NSCLC

Fan Yanga,c, Kaili Longa,c, Yannan Qia,c, Yuwei Daia, Feiyan Pana, Lingfeng Hea, Lindong Yangb( ), Zhigang Guoa( ), Zhigang Hua( )
Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, Jiangsu 210023, China
Department of Obstetrics and Gynecology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu 210018, China

c These authors contributed equally to this work.

Peer review under the responsibility of Chongqing Medical University.

Show Author Information

References

【1】
【1】
 
 
Crossref Google Scholar
Genes & Diseases
Volume 13 Issue 4,
July 2026
DOI: 10.1016/j.gendis.2025.101813

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Yang F, Long K, Qi Y, et al. APE1 inhibition-promoted pyroptosis triggers T-cell infiltration and enhances anti-tumor immunity in NSCLC. Genes & Diseases, 2026, 13(4). https://doi.org/10.1016/j.gendis.2025.101813

3

Views

0

Downloads

0

Crossref

0

Web of Science

0

Scopus

0

CSCD
Received: 10 March 2025
Published: 14 August 2025
© 2025 The Authors.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).